Comparison of Efficacy and Safety of XEN45 Implant Versus Trabeculectomy in Asian Eyes.

Szczegóły
Abstrakt

Tytuł:: Comparison of Efficacy and Safety of XEN45 Implant Versus Trabeculectomy in Asian Eyes.
Autorzy:: Kee AR; National Healthcare Group Eye Institute, Tan Tock Seng Hospital.
Vivien Yip CH; National Healthcare Group Eye Institute, Tan Tock Seng Hospital.
Chua CH; National Healthcare Group Eye Institute, Tan Tock Seng Hospital.
Bryan Ang CH; National Healthcare Group Eye Institute, Tan Tock Seng Hospital.
Jeremy Hu Y; National Healthcare Group Eye Institute, Tan Tock Seng Hospital.
Guo X; National Healthcare Group Eye Institute, Tan Tock Seng Hospital.
Leonard Yip WL; National Healthcare Group Eye Institute, Tan Tock Seng Hospital.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Źródło:: Journal of glaucoma [J Glaucoma] 2021 Dec 01; Vol. 30 (12), pp. 1056-1064.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: <2015- > : Philadelphia, PA : Wolters Kluwer Health, Inc.
Original Publication: New York, N.Y. : Raven Press, c1992-
MeSH Terms:: Phacoemulsification*
Trabeculectomy*
Antiglaucoma Agents ; Humans ; Intraocular Pressure ; Retrospective Studies ; Treatment Outcome
References:: Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189–206.
Lewis RA. Ab interno approach to the subconjunctival space using a collagen glaucoma stent. J Cataract Refract Surg. 2014;40:1301–1306.
Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy. Ophthalmology. 2017;124:1579–1588.
Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Standalone ab interno gelatin stent versus trabeculectomy: post-operative interventions, visual outcomes, and visits. Ophthalmol Glaucoma. 2018;1:189–196.
Marcos Parra MT, Salinas Lopez JA, Lopez Grau NS, et al. XEN implant device versus trabeculectomy, either alone or in combination with phacoemulsification, in open-angle glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2019;257:1741–1750.
Wagner FM, Schuster AK, Emmerich J, et al. Efficacy and safety of XEN(R)-implantation vs. trabeculectomy: data of a “real-world” setting. PLoS One. 2020;15:e0231614.
Theilig T, Rehak M, Busch C, et al. Comparing the efficacy of trabeculectomy and XEN gel microstent implantation for the treatment of primary open-angle glaucoma: a retrospective monocentric comparative cohort study. Sci Rep. 2020;10:19337.
Tan C, Chew PT, Lum WL, et al. Trabeculectomy—success rates in a Singapore hospital. Singapore Med J. 1996;37:505–507.
Wong JS, Yip L, Tan C, et al. Trabeculectomy survival with and without intra-operative 5-fluorouracil application in an Asian population. Aust N Z J Ophthalmol. 1998;26:283–288.
Husain R, Clarke JC, Seah SK, et al. A review of trabeculectomy in East Asian people—the influence of race. Eye (Lond). 2005;19:243–252.
Reitsamer H, Sng C, Vera V, et al. Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2019;257:983–996.
Heidinger A, Schwab C, Lindner E, et al. A retrospective study of 199 Xen45 stent implantation from 2014 to 2016. J Glaucoma. 2019;28:75–79.
Karimi A, Lindfield D, Turnbull A, et al. A multi-centre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgery. Eye (Lond). 2019;33:469–477.
Hohberger B, Welge-Lüßen UC, Laemmer R. MIGS: therapeutic success of combined Xen Gel Stent implantation with cataract surgery. Graefes Arch Clin Exp Ophthalmol. 2018;256:1–5.
Widder RA, Dietlein TS, Dinslage S, et al. The XEN45 Gel Stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profile, and rates of re-surgery after 261 surgeries. Graefes Arch Clin Exp Ophthalmol. 2018;256:765–771.
Mansouri K, Guidotti J, Rao HL, et al. Prospective evaluation of standalone XEN gel implant and combined phacoemulsification-XEN gel implant surgery: 1-year results. J Glaucoma. 2018;27:140–147.
Fea A, Bron A, Economou M, et al. European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma. J Cataract Refract Surg. 2020;46:441–450.
Hu JY, Ang BCH, Yip LW. Efficacy of the XEN gel stent on intraocular pressure lowering in East Asian eyes. Int Ophthalmol. 2020;40:1191–1199.
Shaarawy T, Sherwood M, Grehn F. World Glaucoma Association (WGA) Guidelines on Design and Reporting of Glaucoma Surgical Trials. Amsterdam: Kugler Publications; 2009.
Panarelli JF, Yan DB, Francis B, et al. XEN gel stent open conjunctiva technique: a practical approach paper. Adv Ther. 2020;37:2538–2549.
Ibáñez-Muñoz A, Soto-Biforcos VS, Chacón-González M, et al. One-year follow-up of the XEN® implant with mitomycin-C in pseudoexfoliative glaucoma patients. Eur J Ophthalmol. 2019;29:309–314.
Pérez-Torregrosa VT, Olate-Pérez Á, Cerdà-Ibáñez M, et al. Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions. Arch Soc Esp Oftalmol. 2016;91:415–421.
De Gregorio A, Pedrotti E, Russo L, et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2018;38:1129–1134.
Ozal SA, Kaplaner O, Basar BB, et al. An innovation in glaucoma surgery: XEN45 gel stent implantation. Arq Bras Oftalmol. 2017;80:382–385.
Galal A, Bilgic A, Eltanamly R, et al. XEN glaucoma implant with mitomycin C 1-year follow-up: result and complications. J Ophthalmol. 2017;2017:5457246.
Song BJ, Ramanathan M, Morales E, et al. Trabeculectomy and combined phacoemulsification-trabeculectomy: outcomes and risk factors for failure in primary angle closure glaucoma. J Glaucoma. 2016;25:763–769.
Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001;10:237–249.
The Advanced Glaucoma Intervention Study (AGIS): XI. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol. 2002;134:481–498.
Buffault J, Graber M, Bensmail D, et al. Efficacy and safety at 6 months of the XEN implant for the management of open angle glaucoma. Sci Rep. 2020;10:4527.
Tan SZ, Walkden A, Au L. One-year result of XEN45 implant for glaucoma: efficacy, safety, and post operative management. Eye (Lond). 2018;32:324–332.
Gillmann K, Bravetti GE, Rao HL, et al. Combined and stand-alone XEN45 gel stent implantation: 3-year outcomes and success predictors. Acta Ophthalmol. 2020;99:e531–e539.
Directions for the use for the XEN glaucoma treatment system. 2017. Available at: https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/labeling/xen/dfu_xen_glaucoma_treatment_system_us_feb2017.pdf . Accessed April 22, 2021.
Vera V, Gagne S, Myers JS, et al. Surgical approaches for implanting Xen Gel Stent without conjunctival dissection. Clin Ophthalmol. 2020;14:2361–2371.
Substance Nomenclature:: 0 (Antiglaucoma Agents)
Entry Date(s):: Date Created: 20211103 Date Completed: 20211223 Latest Revision: 20230912
Update Code:: 20240105
DOI:: 10.1097/IJG.0000000000001954
PMID:: 34731866
: Czasopismo naukowe

Prcis: Combined phacoemulsification and trabeculectomy is able to achieve greater reduction in intraocular pressure (IOP), higher rates of complete surgical success and fewer postoperative manipulations and visits compared with combined phacoemulsification and Xen implantation in glaucomatous eyes.
Purpose: Our study aims to compare and understand the differences between the efficacy and safety of XEN45 implantation and trabeculectomy in Asian eyes with glaucoma.
Materials and Methods: This was a retrospective, single-center, comparative study of consecutive patients who underwent combined phacoemulsification and trabeculectomy (Phaco-Trab) from January 2013 to June 2014 and combined phacoemulsification and XEN45 implantation (Phaco-Xen) from May 2017 to September 2018 in a tertiary Ophthalmology center in Singapore. Outcome measures included IOP, number of anti-glaucoma eyedrops, success rate, factors leading to success/failure, number of postoperative interventions and visits required, and surgical complications.
Results: A total of 137 eyes (91 Phaco-Trab, 46 Phaco-Xen) were included. Phaco-Trab group had greater mean IOP reduction at all time points beyond postoperative month (POM) 1 (mean difference 2.9 to 3.8 mm Hg; P<0.05), and greater reduction in mean number of antiglaucoma eyedrops beyond POM3, thought this was not statistically significant. At POM12, complete success was achieved in 83.5% in Phaco-Trab and 52.2% of Phaco-Xen group, respectively (P<0.001). There was no significant factor associated with surgical failure, other than the difference in surgical procedure. Phaco-Trab group required fewer number of postoperative interventions (P=0.009), with only a mean of 0.1 bleb interventions required per patient, versus 1.5 in Phaco-Xen group (P<0.001). Safety profiles in both groups were comparable, with no statistically significant difference in intraoperative/postoperative complications.
Conclusion: Phaco-Trab has significantly higher reduction in both IOP and number of antiglaucoma medications compared with Phaco-Xen group, with greater surgical success and fewer postoperative manipulations and visits. Safety profiles were comparable.
Competing Interests: Disclosure: The authors declare no conflict of interest.
(Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Informacja